60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Construction In Progress : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Construction In Progress?

60 Degrees Pharmaceuticals Construction In Progress Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Construction In Progress Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Construction In Progress

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial							-	-	-	-	-

60 Degrees Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

SXTP:USA

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.